ICFL 2019, Berlin - Program

Program

Thursday, 27 June 2019

16:00 – 18:20

 

Welcome address

 

Keynote Lecture:

  • What is NAFLD - NASH and how it is defined

       Jean-Francois Dufour, University of Bern, Switzerland

 

Keynote Lecture:

  • Global Epidemiology & Outcomes of the NAFLD

       Zobair Younossi, Inova Fairfax Hospital, USA

 

Debate:

  • Should I be looking for NASH in my clinic? 

       PROJerome Boursier, Angers University Hospital, France

       vs.

       CON - Mark Walker, Newcastle University, UK

 

Debate, open discussion and Vote

18:20
Networking Reception

 

 

Friday, 28 June 2019

08:00 – 08:45
Morning Networking
08:45 – 09:15

Keynote lecture: 

  • Biomarkers in NAFLD - If not a biopsy, what - and why

       Quentin Anstee, Newcastle University, UK

09:15 – 11:15

 

 

 

 

 

Session 1: What tools do we have to assess disease severity in NAFLD

 

Blood Tests

 

  • Routine blood tests and Simple Scores in NAFLD

       Salvatore Petta, University of Palermo, Italy

  • New Technologies: Metabolomics, Genomics & Collagen Biomarkers

       Detlef Schuppan, Institute of Translational Immunology, Germany


MRI and Ultrasound

 

  • How to use imaging to evaluate NASH in the clinic – practical approaches for use in the real world?

       Manuel Romero Gomez, Institute of Biomedicine of Seville, Spain

  • Ultrasound-based elastography techniques: TE, ARFI & SSI

       Laurent Castera, University of Paris-VII, France

  • MR-based assessment of inflammation and fibrosis

       Stefan Neubauer, Oxford University, UK

 

Panel Discussion

11:15 – 11:45Coffee break, Exhibition & Poster Viewing

11:45 – 13:15

 

 

 

 

 

 

 

 

 

Session 2: Screening - How should I evaluate NASH in my Clinic?  

 

  • Gastro/Hepatologist perspective  

       Lawrence Serfaty, University of Strsbourg, France

  • Diabetes perspective

       Gianluca Perseghin, University of Milano-Bicocca, Italy

 

Case presentation


Panel discussion 

13:15 – 14:15

Lunch, Exhibition & Poster Viewing

14:15 – 16:00

 

 

 

 

 

 

 

 

 

Session 3: Treating the Metabolic Syndrome in patients with NAFLD

 

  • Medical Therapy for T2DM

       Michael Roden, German Center of Diabetology, Germany

  • Medical Therapy for Dyslipidaemia

       Dirk Muller-Wieland, Aachen University Hospital, Germany

 

Case presentation

 

Panel discussion

16:00 – 16:30Coffee Break, Exhibition & Poster Viewing

16:30 – 18:30

 

 

 

 

 

 

 

Session 4: Treating NAFLD in patients with the Metabolic Syndrome: Current Options

 

  • Dietary Management

       Shira Zelber Sagi, Tel Aviv Medical Center, and School of Public oooHealth, the University of Haifa, Israel

  • Alcohol in NAFLD: an oxymoron or an important cofactor?

       Philip Newsome, University of Birmingham, UK

  • Current available pharmacological therapeutic options for NAFLD using drugs available today

       Kris Kowdley, Swedish Medical Center, USA

  • Bariatric surgery for NAFLD

       Sebastian Mueller, University of Heidelberg, Germany

 

Case presentation

 

Panel discussion

18:30
"Meet with the Professor" Reception

 

Saturday, 29 June 2019

08:00 – 08:45
Morning Networking

08:45 – 10:45

 

 

 

Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow

 

Keynote Lecture:

  • NAFLD Pathophysiology: Targets for Novel Treatments

       Frank Tacke, Aachen University Hospital, Germany


Drug Targets in Phase 2/3 Trials – evidence base and status update

 

  • Bile acid signaling pathways (FXR/FGF19)  

       Michael Trauner, Medical University of Vienna, Austria

  • Metabolic Pathways: Insulin Signaling, PPARs, THRb 2

       Rifaat SafadiHadassah Hebrew University, Israel

  • Trials targeting fibrosis

       Jörn Schattenberg, University Medical Center Mainz, Germany

 

Panel Discussion

10:45 – 11:15
Coffee Break, Exhibition & Poster Viewing

11:15 – 12:30

 

 

 

 

 

 

 

 

 

Session 6: Drug development overview & Clinical Pharmacology in Practice

 

Keynote Lecture:

  • Why too many strategies are failing and do not continue?

       Arun Sanyal, Virginia Commonwealth University, USA


  • DILI in NAFLD: How to assess if a NASH drug is causing liver injury

       Guru Aithal, Nottingham University, UK

 

Panel discussion 

12:30 – 14:00Lunch Break, Exhibition & Poster Viewing

14:00 – 15:45

 

Session 7: NAFLD & Malignancy

 

  • Mechanisms of obesity and NASH related carcinogenesis 

       Mathias Heikenwalder, German Cancer Research Center, Germany

  • HCC Surveillance in NAFLD – who, how and should you?

       Helen Reeves, Newcastle University, UK

  • Extra-hepatic malignancies in NAFLD

       Elisabetta Bugianessi, University of Turin, Italy

 

Case presentation


Panel discussion 

15:45 – 16:15Summing up & Closing Remarks
16:15 - 17:00Informal Discussions and Q&A with Faculty over tea/coffee



Keep Me Updated


​​​ ​​​​​ ​​​​​ ​​​​​